SCHEMBL963877

SCHEMBL963877

O=C(Nc1ccccc1-c1cn2c(CN3CCNCC3)csc2n1)c1cnc2ccccc2n1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
SIRT1 Q96EB6 15/20 1.00
CHRM2 P08172 1/20 1.00
ADRA2A P08913 1/20 1.00
CHRM1 P11229 1/20 1.00
SLC6A2 P23975 1/20 1.00
SIRT2 Q8IXJ6 1/20 1.00
SIRT3 Q9NTG7 1/20 1.00
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
CHEK1 O14757 1/20 0.40
JAK3 P52333 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29488567 1.00 SIRT1 (1.00) SIRT1CHRM2ADRA2ACHRM1SLC6A2
Hydrochloric Acid SCHEMBL16372055 0.99 SIRT1 (0.98) SIRT1CHRM2ADRA2ACHRM1SLC6A2
Hydrochloric Acid SCHEMBL30156752 0.99 SIRT1 (0.98) SIRT1CHRM2ADRA2ACHRM1SLC6A2
SCHEMBL2740335 0.93 SIRT1 (0.86) SIRT1CHRM2ADRA2ACHRM1SLC6A2
SCHEMBL2740379 0.92 SIRT1 (0.85) SIRT1CHRM2ADRA2ACHRM1SLC6A2
SCHEMBL2624518 0.92 SIRT1 (0.85) SIRT1CHRM2ADRA2ACHRM1SLC6A2
SCHEMBL2740334 0.92 SIRT1 (0.85) SIRT1CHRM2ADRA2ACHRM1SLC6A2
SCHEMBL2740430 0.91 SIRT1 (0.83) SIRT1CHRM2ADRA2ACHRM1SLC6A2
SCHEMBL2624519 0.90 SIRT1 (0.82) SIRT1CHRM2ADRA2ACHRM1SLC6A2
SCHEMBL2740333 0.90 SIRT1 (0.82) SIRT1CHRM2ADRA2ACHRM1SLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 468 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250144056-A1 ANTIMICROBIAL HOST DEFENSE PEPTIDE-INDUCING COMPOSITIONS AND METHODS OF PRODUCTION AND USE THEREOF BOARD OF REGENTS FOR THE OKLAHOMA AGRICULTURAL AND MECH COLLEGES (US) 2025-05-08 US claimed
EP-3474834-B1 STIMULATING PLATELET FORMATION WITH BEZAFIBRATE, RESVERATROL OR SRT1720 TO TREAT THROMBOCYTOPENIA THE GENERAL HOSPITAL CORP DBA MASSACHUSETTS GENERAL HOSPITAL (US) 2025-04-09 EP claimed
CN-119488447-A Application of SRT1720 in preparation of skin antioxidant repairing agent 大连大学 2025-02-21 CN claimed
CN-119488524-A Collagen regeneration preparation 大连大学 2025-02-21 CN claimed
US-20250032581-A1 COMPOSITIONS AND ARTICLES COMPRISING AN ADNF POLYPEPTIDE RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) 2025-01-30 US claimed
US-20240335473-A1 USE OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA COACTIVATOR 1-ALPHA (PGC1ALPHA) AGONISTS TO IMPROVE EX VIVO EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES (TILS) UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2024-10-10 US claimed
US-20240156973-A1 OSTEOTROPIC COMPOSITIONS AND USES THEREOF PURDUE RESEARCH FOUNDATION 2024-05-16 US claimed
EP-4340890-A1 OSTEOTROPIC COMPOSITIONS AND USES THEREOF Purdue Research Foundation (US) 2024-03-27 EP claimed
EP-3384007-B1 IMPROVED METHODS FOR REPROGRAMING NON-PLURIPOTENT CELLS INTO PLURIPOTENT STEM CELLS BEIHAO STEM CELL AND REGENERATIVE MEDICINE RES INSTITUTE CO LTD (CN) 2024-03-27 EP claimed
US-20240041767-A1 Mitochondria-Enriched Extracellular Vesicles DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) 2024-02-08 US claimed
CN-114432309-A Method for improving activity of nicotinamide phosphoribosyltransferase and composition thereof 中国科学院深圳先进技术研究院 2022-05-06 CN claimed
CN-108934168-B Improved methods for reprogramming non-pluripotent cells to pluripotent stem cells 北昊干细胞与再生医学研究院有限公司 2022-05-03 CN claimed
US-20180362650-A1 PD-1 SIGNAL INHIBITOR COMBINATION THERAPY KYOTO UNIVERSITY (JP) 2018-12-20 US claimed
WO-2017123161-A9 INHIBITION OF INTRACELLULAR GROWTH OF MYCOBACTERIUM SPECIES AND ITS APPLICATIONS AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2018-11-15 WO claimed
EP-3388084-A1 PD-1 SIGNAL INHIBITOR COMBINATION THERAPY Kyoto University (JP) 2018-10-17 EP claimed
WO-2017123161-A1 INHIBITION OF INTRACELLULAR GROWTH OF MYCOBACTERIUM SPECIES AND ITS APPLICATIONS AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2017-07-20 WO claimed
US-20160145581-A1 COMPOSITIONS AND METHODS FOR REPROGRAMING NON-PLURIPOTENT CELLS INTO PLURIPOTENT STEM CELLS HONG GUAN, LTD. (CN) 2016-05-26 US claimed
EP-3019596-A1 COMPOSITIONS AND METHODS FOR REPROGRAMING NON- PLURIPOTENT CELLS INTO PLURIPOTENT STEM CELLS Hong Guan Ltd. (CN) 2016-05-18 EP claimed
US-20150133527-A1 REGULATION OF CARDIAC SODIUM CHANNELS BY SIRT1 AND SIRT1 ACTIVATORS UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION 2015-05-14 US claimed
WO-2015003643-A1 COMPOSITIONS AND METHODS FOR REPROGRAMING NON- PLURIPOTENT CELLS INTO PLURIPOTENT STEM CELLS HONG GUAN LTD. (CN) 2015-01-15 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240335473-A1 USE OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA COACTIVATOR 1-ALPHA (PGC1ALPHA) AGONISTS TO IMPROVE EX VIVO EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES (TILS) PPARD, PPARA, PPARG SIRT1 36/4885CHRM2 2598/4885ADRA2A 472/4885
US-20160145581-A1 COMPOSITIONS AND METHODS FOR REPROGRAMING NON-PLURIPOTENT CELLS INTO PLURIPOTENT STEM CELLS AHCY, GSKIP, AHCYL1 SIRT1 206/4885CHRM2 1550/4885ADRA2A 2486/4885
US-20150133527-A1 REGULATION OF CARDIAC SODIUM CHANNELS BY SIRT1 AND SIRT1 ACTIVATORS SIRT1, SIRT5, SIRT3 SIRT1 1/4885CHRM2 1303/4885ADRA2A 564/4885
US-20240156973-A1 OSTEOTROPIC COMPOSITIONS AND USES THEREOF SOST, BMP2, BMP6 SIRT1 4605/4885CHRM2 4218/4885ADRA2A 928/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.